Should Investors Buy Moderna Stock for Its Coronavirus Vaccine?

On the surface, Moderna (NASDAQ: MRNA) looks like a great growth stock backed by its coronavirus vaccine. And the biotech also has potential to use its messenger RNA technology to develop other vaccines in its pipeline.

But in this video from Motley Fool Live recorded on Nov. 23, Corinne Cardina, bureau chief of healthcare and cannabis, and Brian Orelli, Fool.com contributor, point out issues with Moderna's current valuation, especially compared to other biotechs that already have drugs on the market.

Continue reading

Source Fool.com